Overview

CHG Combined With Venetoclax and Azacytidine in Newly Diagnosed AML

Status:
NOT_YET_RECRUITING
Trial end date:
2028-12-01
Target enrollment:
Participant gender:
Summary
The goal of this phase 2 trial is to test the safety and efficacy of CHG Combined With Venetoclax in treating patients with newly diagnosed AML.
Phase:
PHASE2
Details
Lead Sponsor:
Navy General Hospital, Beijing
Treatments:
Azacitidine
venetoclax